Radiation-Chemical Combo Enlists Killer T-Cells Against Lymphoma

Forever in search of a way to enlist the immune system to fight the growth of cancer in the body, researchers in England think they might have the latest answer.

University of Manchester researchers believe that a chemical known as R848 kick-starts immune cells by stimulating receptors on the cell surface. When researchers injected mice with R848, they saw an expansion in the blood of killer T-cells.

Radiation-chemical combo four times more effective

When they used R848 along with radiotherapy, they found that subjects (the mice) were four times more likely to experience long-term survival with lymphoma patients then if they received radiation therapy alone.

Their findings have been published in the journal of the American Society of Hematology, Blood.

Dr. Simon Dovedi of the University of Manchester's Institute of Cancer Sciences and Manchester Academic Health Science Centre commented:

"This could give patients a better response to conventional therapies through the generation of a lymphoma-specific immune response against tumor cells. This could be the key to ensuring long-term survival in more patients and reducing the number of relapses after initial therapy."

Very few side effects, long-term survival

Researchers saw little in the way of side effects or adverse events from R848 and radiotherapy. Every mouse with lymphoma treated with this combination experienced long-term survival, compared to a little more than one-quarter of the mice receiving radiotherapy alone.

Further, they believe that the activation of the immune system prevents cancer from recurrence.

Professor Chris Bunce of Leukemia & Lymphoma Research stated:

"These results are hugely promising. One of the major obstacles to long-term successful treatment for many types of lymphoma has been relapse after initial successful treatment. Treatment with R848 can prime T cells to recognize various tumor-associated antigens, protecting patients from the return of the cancer."

Source: MNT

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...